dm+d

Unassigned

New Medicines

Transfusion-dependent and relapsed/refractory myelodysplastic syndromes (MDS)

Information

New molecular entity
Geron Corporation
Geron Corporation

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

An engineered and modified short oligonucleotide that targets and binds to the active site of telomerase, the biochemical involved in chromosome elongation. In cancer and in aging cells, telomerase either stops functioning or functions improperly
The annual incidence of myelodysplastic syndromes is estimated at 4 per 100,000. However, incidence increases with age, and is 30 per 100,000 per year in people over 70 years of age. The prevalence of myelodysplastic syndromes is approximately 5 per 100,000. [2]
Transfusion-dependent and relapsed/refractory myelodysplastic syndromes (MDS)
Intravenous infusion

Further information

Yes

Evidence based evaluations

Primary or secondary myelofibrosis, intermediate-2 or high-risk, relapsed or refractory - second-line following treatment with a Janus Kinase inhibitor

Information

New molecular entity
Geron Corporation
Geron Corporation

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

An engineered and modified short oligonucleotide that targets and binds to the active site of telomerase, the biochemical involved in chromosome elongation. In cancer and in aging cells, telomerase either stops functioning or functions improperly [1]
Myelofibrosis may be primary (known as chronic idiopathic myelofibrosis), or secondary to either polycythaemia vera or essential thrombocythaemia. The annual incidence of myelofibrosis is approximately 0.75 per 100,000. The median survival is 5 years from onset, but variation is wide; some patients have a rapidly progressing disorder with short survival. The peak incidence of primary myelofibrosis is between 50 and 70 years of age [3]
Primary or secondary myelofibrosis, intermediate-2 or high-risk, relapsed or refractory - second-line following treatment with a Janus Kinase inhibitor
Intravenous infusion